PLUR
Pluri Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$36.31M
P/E Ratio
—
EPS
$-3.31
Beta
0.72
52W High
$6.10
52W Low
$2.82
50-Day MA
$3.40
200-Day MA
$3.93
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
3.63
PEG Ratio
—
About Pluri Inc.
Pluri Inc. is an innovative biotechnology company specializing in regenerative medicine and immunotherapy, focused on developing advanced cell-based therapies for oncology and degenerative diseases. Utilizing its proprietary technology platform, Pluri aims to improve patient outcomes and drive growth through a promising pipeline of therapeutics and strategic collaborations with industry partners. By harnessing the potential of human cells, the company is positioning itself as a key player in the biotechnology sector, committed to delivering transformative solutions that address critical unmet medical needs in the evolving healthcare landscape.
Fundamentals
| Revenue (TTM) | $1.34M |
| Gross Profit (TTM) | 544,000 |
| EBITDA | $-24.43M |
| Operating Margin | -3286.00% |
| Return on Equity | -1022.00% |
| Return on Assets | -50.60% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $-1.46 |
| Price-to-Book | 306.56 |
| Price-to-Sales (TTM) | 27.12 |
| EV/Revenue | 43.66 |
| EV/EBITDA | -1.28 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7.00% |
| Shares Outstanding | $10.77M |
| Float | $4.53M |
| % Insiders | 40.22% |
| % Institutions | 12.56% |
Historical Volatility
HV 10-Day
47.41%
HV 20-Day
39.47%
HV 30-Day
46.28%
HV 60-Day
55.12%
HV Rank
3.2%
Volatility is currently expanding
Data last updated: 4/29/2026